Get the Stockscreener App
4.43
5.34%
-0.25
Pre-market:
4.54
0.11
+2.48%
Evolus Inc stock is traded at $4.43, with a volume of 1.22M.
It is down -5.34% in the last 24 hours and up +3.02% over the past month.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
See More
Previous Close:
$4.68
Open:
$4.6
24h Volume:
1.22M
Relative Volume:
0.95
Market Cap:
$288.22M
Revenue:
$297.18M
Net Income/Loss:
$-51.64M
P/E Ratio:
-5.5148
EPS:
-0.8033
Net Cash Flow:
$-50.72M
1W Performance:
-9.78%
1M Performance:
+3.02%
6M Performance:
-27.26%
1Y Performance:
-65.92%
1-Day Range:
$4.40
$4.635
1-Week Range:
$4.40
$4.91
52-Week Range:
$4.0913
$13.10
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.43 | 288.22M | 297.18M | -51.64M | -50.72M | -0.8033 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus, Inc.(NasdaqGM: EOLS) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 13,669 Shares - MarketBeat
Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 3,119 Shares - MarketBeat
Avelar Rui sells Evolus (EOLS) shares worth $14815 By Investing.com - Investing.com Canada
Evolus CEO Moatazedi sells $64929 in shares - Investing.com
Avelar Rui sells Evolus (EOLS) shares worth $14815 - Investing.com
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan - Stock Titan
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes - Stock Titan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus CEO Moatazedi sells $570k in shares By Investing.com - Investing.com India
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock - MarketBeat
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock By Investing.com - Investing.com Australia
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com Australia
Evolus CEO Moatazedi sells $570k in shares - Investing.com
Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan
(EOLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Dip Buying: What is the earnings history of Evolus IncMarket Sentiment Review & Safe Entry Point Identification - baoquankhu1.vn
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Jobs Data: Whats the beta of Evolus Inc stockTrade Entry Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS - MarketBeat
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Yahoo Finance
Evolus (NASDAQ:EOLS) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Evolus reclassifies Vikram Malik to Class II director to balance board By Investing.com - Investing.com UK
Vikram Malik reclassified to Class II director at Evolus - TradingView
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance - Stock Titan
Evolus, Inc. Announces Executive Changes, Effective March 13, 2026 - marketscreener.com
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus at Leerink Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
New Highs: What is the earnings history of Evolus IncMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Evolus Earnings Call Signals Growth Amid Headwinds - The Globe and Mail
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Market Outlook: What analysts say about Evolus Inc stockTrade Ideas & Short-Term High Return Strategies - baoquankhu1.vn
Bank Watch: Can Evolus Inc navigate macro headwindsPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
(EOLS) Risk Channels and Responsive Allocation - Stock Traders Daily
Can Evolus Inc. stock maintain growth trajectoryChart Signals & Community Consensus Trade Alerts - Naître et grandir
Evolus (NASDAQ:EOLS) Rating Increased to Buy at Wall Street Zen - MarketBeat
Why Evolus Stock Soared Today - AOL.com
Evolus, Inc. (EOLS) matches Q4 earnings estimates - MSN
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Evolus (EOLS), Aldeyra Therapeutics (ALDX) - The Globe and Mail
Data Privacy Compliance Risks Threaten Evolus’s Operations and Financial Health - TipRanks
BTIG Reiterates Buy Rating for Evolus (EOLS) with $13 Target | E - GuruFocus
Evolus (EOLS) Nears Breakeven In Q4 EPS Challenging Prolonged Loss Narratives - simplywall.st
Evolus Q4 2025 slides: revenue growth continues despite forecast miss - Investing.com Australia
EOLS SEC FilingsEvolus 10-K, 10-Q, 8-K Forms - Stock Titan
Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Evolus Up Over 26%, on Pace for Largest Percent Increase Since January 2025 -- Data Talk - 富途牛牛
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):